It is conspicuous that drug firms have only started hiking prices since the Conservative Party started messing around with the National Health Service.
Raising the prices of drugs in a captive market like the NHS means that there is increasingly less money for the provision of care, and increasingly more profit for ‘Big Pharma’.
The Tories won’t mind because it suits their purposes to have an NHS that can’t afford to pay its way – even if this is because prices are corruptly being raised to maximise profits for the greedy.
That’s why a Health Department spokesperson claimed that “The UK has some of the lowest prices for generic drugs in the world” – even though the facts had already been laid out in this Mirror article:
Pharmaceutical firms are “milking” the NHS by hiking drug prices by 2,000%, it has been claimed.
Companies are said to be “de-branding” vital medication and flogging them as generic drugs, meaning the cost to the customer rockets.
The price of some treatments for conditions ranging from high blood pressure to insomnia have spiralled, a Sunday Times investigation found.
It showed the price of a 150ml oral solution of Symmetrel, which treats Parkinson’s disease, rose from £5 to £130 between November 2013 and now – a huge increase of 2,358%.
The drug was de-branded in October last year and sold as amantadine.
While a packet of 250mg capsules of epilepsy drug Mysoline, sold as primidone since October 2013, has shot up from just £12.60 to £93.75.
Join the Vox Political Facebook page.
If you have appreciated this article, don’t forget to share it using the buttons at the bottom of this page. Politics is about everybody – so let’s try to get everybody involved!
Vox Political needs your help!
If you want to support this site
(but don’t want to give your money to advertisers)
you can make a one-off donation here:
Buy Vox Political books so we can continue
fighting for the facts.
Health Warning: Government! is now available
in either print or eBook format here:
The first collection, Strong Words and Hard Times,
is still available in either print or eBook format here: